Edesa Biotech, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
EDSA Nasdaq 2830 www.edesabiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Edesa Biotech, Inc.

Edesa Biotech’s Founder Makes Strategic Investment in the Company - Oct 31st, 2024 12:15 pm
Edesa Biotech Announces Upcoming Conference Schedule - Oct 21st, 2024 12:15 pm
EDSA: EB05 Selected for BARDA-Funded Study in ARDS… - Aug 20th, 2024 12:25 pm
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS - Jun 24th, 2024 12:20 pm
EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo - May 28th, 2024 9:00 am
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results - May 10th, 2024 8:15 pm
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference - Apr 11th, 2024 1:00 pm
Edesa Biotech to Participate in Upcoming Investor Conferences - Apr 2nd, 2024 1:00 pm
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference - Mar 21st, 2024 8:30 pm
Edesa Biotech to Participate in Barclays Global Healthcare Conference - Mar 7th, 2024 12:45 pm
Edesa Biotech to Participate in Upcoming Dermatology Meetings - Mar 4th, 2024 9:30 pm
EDSA: Development of EB05 in ARDS Continues… - Feb 15th, 2024 1:21 pm
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results - Feb 9th, 2024 9:15 pm
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week - Jan 4th, 2024 9:15 pm
EDSA: Updated Phase 3 Protocol for EB05 Trial Approved by Canadian Regulators… - Jan 2nd, 2024 4:06 pm
Edesa Biotech Reports Fiscal Year 2023 Results - Dec 15th, 2023 9:10 pm